ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Central Asian-Mongolian-Iranian celiac disease taskforce: A look into the future- 2026-2035 and beyond.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited data on celiac disease (CeD) from Central Asia and Mongolia. In contrast, data from Iran shows a rapid increase in the number of diagnosed cases since early 2000s. Limited data is available and likely due to low awareness, limited diagnostic access and the current belief that CeD is uncommon.
objectivesThe first international Task Force for CeD met to have a look into the future at the Republican Specialized Centre of Pediatrics, Tashkent, Uzbekistan (March 2026) to (1) focus on diagnosis and prevalence research; (2) promote affordable serological testing for all socio-economic strata; (3) improve involvement of medical sub-specialties; (4) suggest proper gluten-free legislation for wheat food labeling and (5) organize affordable gluten-free food for CeD patients in general. KEY RECOMMENDATIONS (2026-2030): Standardize local tissue transglutaminase antibodies (tTGA) testing to ≤ 5-10$/test; evaluate point-of-care tests in rural clinics Conduct population-based serosurveys in Central Asia, Iran and Mongolia (n ≥ 1000 each) Advocate for mandatory gluten-free labeling standards (≤ 20 ppm) Evaluation of abdominal ultrasound in CeD recognition Establish CeD patient associations to improve patient empowerment in Central Asia, Mongolia and Iran Develop online CeD training modules for clinicians in local languages.
Indexed as
Identifiers
42905255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.